Dr David Granger

Dr David Granger has over 15 years’ experience in drug discovery, working on both small molecule and antibody therapeutic programmes.

Originally trained as a pharmacologist, he joined global pharmaceutical company GSK following a PhD and post-doctoral research position at Imperial College. At GSK David led bispecific antibody programmes utilising different discovery platforms, whilst overseeing multiple collaborations. In 2017, he joined bispecific antibody biotechnology company Crescendo Biologics as a Senior Scientist, leading therapeutic immuno-oncology programmes, and developing and embedding a bispecific discovery platform into the workflow.

David was appointed Director of R&D at newly incorporated NovalGen in 2019, before being promoted to Vice President of R&D in 2021. He leads the R&D team with activities spanning from target identification and antibody discovery through to translational research and IND enabling studies.